Vertex Pharmaceuticals Incorporated (VRTX) on Decifer

Decifer ranks VRTX number 48 of 270 tracked names on durable business quality.

Why it ranks here

• It earns strong returns on the money it puts to work, around 18% and it turns most of its profit into real cash.
• Revenue is expected to grow about 10% a year, profits grew 843% over the past year, and growth is speeding up, not slowing down.
• It keeps a high share of every sale as profit, and that has stayed steady over the years, a sign of real pricing power, with profitability widening as it grows.
• and has the balance sheet to fund its growth.
• It is not watering down its owners with new shares and it returns cash to shareholders.
• Returns of 18% and 843% profit growth reflect deep profitability, but no worldview role keeps the ceiling firm despite momentum of 13 out of 35.

The current read

The evidence on VRTX lines up on the supportive side: the intelligence feed flags this name as connected to what is moving markets now. The independent signals we track are telling the same story.

Themes

• Next-Gen Genetic & RNA/Antibody Therapeutics: Platform breakthroughs in RNA interference, redosable gene therapy and antibody engineering are converting once-undruggable and orphan targets into commercial therapies.

Read the full VRTX research brief · See all quality rankings

Intelligence data powered by Decifer. Not financial advice. For informational purposes only.